CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+4.74%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$601M
AUM Growth
+$601M
(-13%)
Cap. Flow
-$45.3M
Cap. Flow
% of AUM
-7.53%
Top 10 Holdings %
Top 10 Hldgs %
45.47%
Holding
85
New
9
Increased
4
Reduced
19
Closed
15
Top Buys
| 1 |
BLUE
bluebird bio
BLUE
|
$28.9M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$16.9M |
| 3 |
RXDX
Ignyta, Inc.
RXDX
|
$15.5M |
| 4 |
Omeros
OMER
|
$10.9M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$9.97M |
Top Sells
| 1 |
Theravance Biopharma
TBPH
|
$18.9M |
| 2 |
Corbus Pharmaceuticals
CRBP
|
$13.9M |
| 3 |
FWP
Forward Pharma A/S American Depositary Shares
FWP
|
$12.7M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$11.8M |
| 5 |
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
|
$10.1M |
Sector Composition
| 1 | Healthcare | 84.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PTLA
1
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $50.6M | 8.38% | 900,000 +300,000 | +50% | +$16.9M |
|
|
2
Theravance Biopharma
TBPH
$699M
| $37.8M | 6.27% | 950,000 -475,000 | -33% | -$18.9M |
|
|
BLUE
3
DELISTED
bluebird bio
BLUE
| $28.9M | 4.79% | +275,000 | New | +$28.9M |
|
|
QTNT
4
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $26.1M | 4.33% | 3,549,000 +650,000 | +22% | +$4.78M |
|
|
5
Omeros
OMER
$283M
| $25.9M | 4.29% | 1,300,000 +550,000 | +73% | +$10.9M |
|
6
Galapagos
GLPG
$2.07B
| $22.9M | 3.8% | 300,000 | – | – |
|
|
JUNO
7
DELISTED
Juno Therapeutics, Inc.
JUNO
| $22.4M | 3.72% | 750,000 +100,000 | +15% | +$2.99M |
|
|
NVRO
8
DELISTED
NEVRO CORP.
NVRO
| $20.1M | 3.33% | 270,000 -80,000 | -23% | -$5.95M |
|
9
Aclaris Therapeutics
ACRS
$209M
| $19.5M | 3.24% | 720,000 -80,000 | -10% | -$2.17M |
|
10
AnaptysBio
ANAB
$569M
| $19.1M | 3.17% | 799,469 -96,157 | -11% | -$2.3M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $18.6M | 3.09% | 367,900 -232,100 | -39% | -$11.8M |
|
|
KA
12
DELISTED
Kineta, Inc. Common Stock
KA
| $17.8M | 2.95% | 3,804,027 | – | – |
|
13
Clearside Biomedical
CLSD
$28.9M
| $17.7M | 2.93% | 1,940,880 | – | – |
|
14
Minerva Neurosciences
NERV
$16.5M
| $17.7M | 2.93% | 1,997,412 -310,491 | -13% | -$2.75M |
|
|
EGRX
15
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $15.8M | 2.62% | 200,000 | – | – |
|
|
RXDX
16
DELISTED
Ignyta, Inc.
RXDX
| $15.5M | 2.57% | +1,500,000 | New | +$15.5M |
|
|
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $13.1M | 2.17% | 1,000,000 -130,000 | -12% | -$1.7M |
|
|
MTVA
18
MetaVia Inc. Common Stock
MTVA
$15.3M
| $12.3M | 2.04% | 952,798 | – | – |
|
19
Neurocrine Biosciences
NBIX
$13.8B
| $11.5M | 1.91% | 250,000 -50,000 | -17% | -$2.3M |
|
|
ALDR
20
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $10.3M | 1.71% | 900,000 -198,205 | -18% | -$2.27M |
|
|
21
Alnylam Pharmaceuticals
ALNY
$58.5B
| $9.97M | 1.65% | +125,000 | New | +$9.97M |
|
22
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $8.9M | 1.48% | 620,300 | – | – |
|
|
GTHX
23
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $8.37M | 1.39% | +479,986 | New | +$8.37M |
|
24
Heron Therapeutics
HRTX
$207M
| $7.89M | 1.31% | 570,000 -630,000 | -53% | -$8.72M |
|
|
ARRY
25
DELISTED
Array Biopharma Inc
ARRY
| $7.53M | 1.25% | 900,000 | – | – |
|